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Disclaimers:
Research is behind in assessing outcomes for gender diverse
individuals. This talk will be primarily focusing on those who
are born biologically female.

I will try to make this interactive...ish.
Please feel free to ask questions
• I may not know all the answers
• I did not have a chance to change
much of my presentation for our
didactics, so roll with it :)
•

Objectives:
• Review evidence-based, flexible and patient-centered
approaches to contraceptive management in individuals
with reproductive potential
• Discuss updates in contraceptive prescribing and
management
• Highlight considerations for management of contraception
in the time of COVID-19 and in special populations

What we will not cover...
•
•
•
•
•

Extensive detail regarding all forms of contraception
Use of contraceptives for other diagnoses that can be
treated with hormonal therapy, such as endometriosis, etc.
Options counseling for patients currently pregnant
Conception and fertility care
Full spectrum of contraception for gender minority patients

Roadmap for today:
•
•
•
•
•

Introduction
Approach to initiation of contraception
Overview of methods of contraception
Special Considerations
Resources
•
•

•
•

Medical Eligibility and Special Practice Recommendations
Contraception App

Summary
References

Introduction:
•

Nearly all US women at risk for pregnancy have used some form of
contraception at some point

•

Multiple barriers exist for women to obtain contraceptives or use
them effectively or consistently

•

Less than half of women presenting for annual health visits
receive contraceptive or other family planning services

Introduction:
•

45% of US pregnancies
are unplanned
• 54% due to non-use of
contraception

•

41% due to inconsistent
use of method

Intended
55%

Unintended –
Mistimed 27%

Unintended –
Unwanted 18%

Finer LB, Zolna MR. Declines in Unintended Pregnancy in the United States, 2008-2011. N Engl J Med. 2016 Mar 3;374(9):843-52.

Introduction:
•

Unintended pregnancies resulting in births are more likely to
have:
•
•
•
•

inadequate or a delayed initiation of prenatal care,
tobacco and alcohol use during pregnancy,
premature and low-birth-weight infants, and
other risks of physical and mental health problems

Introduction:
•

Despite declining rates of
unintended pregnancy in the
US, major disparities remain

Role of Primary Care in Contraceptive Planning:
• Fertility Goal Assessment
• Pregnancy Risk Factor Consideration
• Safe, effective and reliable contraceptive counseling in the
context of the patient’s overall health

Approach to Initiating Contraception:
• Pregnancy Intendedness
• Patient Values and Preferences
• Efficacy and Safety Profiles

Pregnancy Intendedness Screening:
•

“One Key Question” ®
• Would you like to become pregnant in the next year?
Yes - No - I Don’t Know
•

Benefits:
•
•

•

Quick
Open-ended

Limitations:
•
•

Dichotomous
Little room for ambivalence
https://powertodecide.org/one-key-question

Contraceptive Vital Sign
Questionnaire:
Promoting Safe Prescribing in Primary Care With a
Contraceptive Vital Sign: A Cluster-Randomized
Controlled Trial
Schwarz et al
Annals of Family Medicine
http://www.annfammed.org/content/10/6/516.full.pdf

Overview of Contraceptive Methods:
•
•
•
•
•
•
•
•
•

Intrauterine devices
Progestin-only contraceptives
Combined hormonal contraceptives
Emergency contraceptive pills
Barrier contraceptive methods
Fertility Awareness-Based Methods
Lactational Amenorrhea Method
Coitus Interruptus
Female and Male Sterilization

Overview of Contraceptive Methods:
Contraceptive Use (U.S. Data 2018)
• 65% of US women aged 15-49 were
using contraception
• Percent using:
• the pill: 14.0%
• long-acting reversible
•
•

contraception (IUD or implant):
10.4%
female sterilization: 18.1%
male sterilization: 5.6%

Combined Estrogen and Progestin Pill, Patch, Ring:
•

Mostly the same w/ some
nuance

•

Improved bleeding profile
w/ higher ethinyl estradiol,
but ↑ risk of VTE and EE
related side effects

•

Consider also prescribing
EC (more on this later)

•

Extended cycle options

https://client.formularynavigator.com/Search.aspx?siteCode=1726717632&drugSortBy=brand&drugSortOrder=asc&targetScreen=3&drugBrandListBaseT
C=endocrine+and+metabolic+-+drugs+to+treat+diabetes+and+regulate+hormones%7ccontraceptives+-+products+for+birth+control

Extended Cycle OCPs:
•

Risks are similar to
traditional OCPs

•

Preparations can range
from 84 to 365 days

•

May be of benefit to
those desiring to avoid
monthly menses due to
symptoms

New Patch: Levonorgestrel/Ethinyl Estradiol
•
•
•
•
•

Twirla ®
FDA approved February 2020
120mg levonorgestrel / 30 mg ethinyl estradiol daily
1 patch weekly x3 weeks, 1 week patch free
Limitations:
•
•

Approved for BMI < 30 ONLY
Cost: $200/month, $25 w/ savings program

New Ring: Segesterone Acetate and
Ethinyl Estradiol Vaginal Ring
•

Annovera ®

•

FDA approved February 2020

•

150 mg Segesterone acetate /13 mg ethinyl estradiol per day

•

“The only long-lasting, reversible contraception that is patient
controlled and procedure free.”

•

Ring is inserted for 21 continuous days and removed for 7 days for
13 cycles; no refrigeration needed

Limitations for use:
•
•

Annovera has not been adequately studied in
individuals with a body mass index >29 kg/m2.
Cost ~$2000; Coverage is limited

Progestin only contraception:
•
•
•
•
•

Norethindrone (“Mini pill”)
NEW: Drosperinone Progesterone-only pill (Slynd ®)
Depot medroxyprogesterone acetate (Depo-Provera ®)
Etonogestrel implant (Nexplanon ®)
Levonorgestrel-releasing intrauterine system (Mirena ®,
Liletta ®, Skyla ®, Kyleena ®)

New: Drosperinone Progesterone-only Pill
•
•
•
•
•

•

Slynd ®
FDA Approved June 2019
4mg Drosperinone (Spironolactone derivative)
• 24 active / 4 inactive
Inhibits ovulation and thickens cervical mucus
Limitations:
• Cost: $200/month, or savings program - $25/3 months
• Side effects / Precautions: irregular bleeding, Hyperkalemia
Does not appear to be significant decrease in efficacy in BMI >30 or
age > 35

Kimble et al. A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of
the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg
using a 24/4-day regimen. Contraception: X. 2020 Jan 30;2:100020.

Updates in Emergency Contraception:
•

Oral
•
•

•

Levonorgestrel 1.5mg once (Plan B ®)
Ulipristol acetate 30mg once (Ella ®)

IUD
•

Copper T380A IUD (Paragard ®)

•

Levonorgestrel IUD?

Intrauterine Devices
•
•

Non-hormonal option: Copper-T 380A (“Paragard ®)
Hormonal (Levonorgestrel) options:
•
•
•
•

Mirena ® 52mg
Liletta ® 52mg
Kyleena ® 19.5mg
Skyla ® 13.5mg

RAPID-EC Trial:
(Randomized Controlled Trial Assessing Pregnancy with
Intrauterine Devices for Emergency Contraception)
First and only RCT, noninferiority trial comparing
levonorgestrel 52mg IUD to copper IUD for EC within 5 days
of unprotected intercourse
• Multicenter, participant-blinded
• Primary outcome:
•

•
•

Positive pregnancy test 1 month after IUD insertion
Noninferiority margin calculated at 2.5% points

Extended use of Etonogestrel implant:
•
•

Currently FDA approved for 3 years
May be used off-label up to 5 years
• Study by McNicholas et al.
• Prospective study enrolling women using etonogestrel implant or 52mg
levonorgestrel IUD

•
•

N=291 implant users

• Assessed unintended pregnancy rate & serum etonogestrel levels
Conclusion:
• Implant continues to be highly effective for at least 2 yrs additional use AND
serum levels remained above ovulation threshold of 90 pg/mL for all BMI
classes

Special Considerations:
• Contraceptive use in transgender and gender
non-conforming individuals
• Contraception in the time of COVID-19

Contraceptive use in transgender and gendernonconforming individuals:
Assess pregnancy goals if pregnancy risk exists
• Important not to make assumptions – ask open ended
questions
• Special considerations:
•

•
•
•
•

Interactions with hormonal therapy? Consider avoiding E
Desires to have or not have monthly menses
Apprehension re: pelvic exam
Hx of uterine or pelvic reconstructive surgery?

Contraception in the time of COVID-19:
•

Contraceptive Counseling and Prescribing via telehealth
•
•

Safe and important for access (removes barriers, e.g. travel,
childcare, time off work)
Assessment does not always require an in person physical exam
• Caveat: procedural contraception
• HTN and migraine w/ aura, tobacco use, hx of VTE: contraindication to

estrogen; review chart for BPs and documented “migraine” history, inquire
further

•
•
•

Consider subcutaneous Depo-Provera for self-administration
Consider providing refills for the year
If currently has LARC, assess FDA approved and evidence-based duration

Quick Start Algorithm

for Hormonal Contraception 2

Patient requests new birth control method:
Pill, Patch, Ring, Injection, Implant

< 7 days ago.

> 7 days ago.

First day of last menstrual period (LMP) is:

Unprotected sex since last LMP?

Start method today.
A backup method is not
needed for injection.
If LMP was 5-7 days ago and patient
chose pill, patch, ring or implant,
a backup method is needed for 7 days

yes

no

Urine pregnancy test: negative1

Advise patient that early pregnancy is possible,
but hormones would not cause harm.2

Start method
today.
A backup method
is needed for
7 days.

Does the patient want to start a new method now?

no

yes

If the patient had unprotected sex < 5 days ago,
offer Ullipristal or Levonorgestrel emergency
contraception (EC) today.3

If the patient had unprotected sex < 5 days ago,
offer Levonorgestrel EC today.3

Offer prescription, advance supply, or appointment
for chosen method. Advise patient to use and
alternate method until next menses.

Start method today.
A backup method is needed for 7 days.
Repeat pregnancy test (home or office)
in 2-4 weeks.1

Start pill, patch, or ring within 5 days
after the start of next period.
Return for implant insertion within 5 days
after the start of next period.
Return for injection within 7 days
after the start of next period.

A note on other non-prescription birth control methods…
Non-Prescription Birth Control Methods
Method

External
Condom

How
well
does it
work?

How to Use

Pros

Cons

82%

Use a new condom each time
you have sex
After sex, pull out before penis
gets soft while holding onto the
condom’s rim
Use a polyurethane condom if
you are allergic to latex

Can buy at many stores
Can put on as part of sex play/
foreplay
Can help prevent early
ejaculation
Can be used for vaginal, oral,
and anal sex
Protects against HIV and many
other sexually transmitted
infections (STIs)
Can be used while breastfeeding

Can decrease sensation
Can cause loss of erection
Can break or slip off

79%

Use a new condom each time
you have sex
Use extra lubrication as needed

Can put in as part of sex play/
foreplay
Can be used for anal and
vaginal sex
May increase pleasure when
used for vaginal sex
Good for people with latex
allergy
Protects against HIV and other
STIs
Can be used while breastfeeding

Can decrease sensation
May be noisy
May be hard to insert
May slip out of place
during sex
The Internal Condom is only
available with a prescription

72%

Insert more spermicide each
time you have sex
Insert spermicide deep into
vagina shortly before sex
May use with condoms (to
protect against HIV and STIs)

Can buy at many stores
Can put in as part of sex play/
foreplay
Comes in many forms
Can be used while
breastfeeding

May raise the risk of getting
HIV or other STIs
May irritate vagina or penis
Cream, gel, and foam can
be messy
Does not protect against
HIV or other STIs

Pull penis out of vagina before
ejaculation (that is, before
coming)

Costs nothing
Can be used while
breastfeeding

Less pleasure for some
Doesn’t work if penis is not
pulled out in time
Does not protect against
HIV or other STIs
Must interrupt sex

(Latex or
Polyurethane)

Method

Fertility
Awareness

(Polyurethane)

Spermicide
Cream, gel,
sponge, foam,
inserts, film

Withdrawal
Pull-out

78%

How to Use

Pros

Cons

76%

Predict fertile days by:
1. taking temperature daily
2. checking vaginal mucus for
changes; AND/OR
3. keeping a record of your
periods
It works best if you use more
than one of these
Avoid sex or use condoms/
spermicide during fertile days.
For full instructions:
http://www.americanpregnancy.
org/preventingpregnancy/
fertilityawarenessNFP.html

Costs little
Can be used while
breastfeeding
Can help with avoiding or
trying to become pregnant

Must use another method
during fertile days
Works best if you have
regular cycles
Many things to remember
with this method
Does not protect against
HIV or other STIs

95%

Nurse at least every 4 hours
during the day
Nurse at least every 6 hours
during the night
Must breastfeed only—
no bottles, formula, or food.
Works only until:
1. You get your first period
OR
2. 6 months after childbirth
(whichever comes first)

Costs nothing

Must breastfeed only: can’t
use formula or baby food
Must breastfeed often
Does not protect against
HIV or other STIs

58-94%
Ulipristal
acetate
EC works
better than
progestin
EC if
you are
overweight
Ulipristal
acetate
EC works
better than
progestin
EC in the
2-5 days
after sex

Works best the sooner you take
it after unprotected sex
You can take EC up to 5 days
after unprotected sex
If pack contains 2 pills, take both
together

Can be used while
breastfeeding
Available at pharmacies,
health centers, or health care
providers: Call ahead to see if
they have it
You can get some brands
without a prescription

May cause stomach upset
or nausea
The next period may come
early or late
May cause spotting
Does not protect against
HIV or other STIs
Ulipristal acetate EC is only
available with a prescription
People under age 17
need a prescription for
some brands.
May cost a lot

Natural Family
Planning

Breastfeeding
Internal
Condom

How
well
does it
work?

Reproductive Health Access Project / August 2018

www.reproductiveaccess.org

(No Periods)
Lactation
Amenorrhea
Method (LAM)

Emergency
Contraception
Pills
Progestin EC
(Plan B One-Step®
and others) and
ulipristal acetate
EC (ella®)

Reproductive Health Access Project / August 2018

www.reproductiveaccess.org

Nonhormonal: Vaginal Gel
•
•
•
•
•
•
•

Phexxi ®
FDA Approved May 2020
Spermicidal Gel to inhibit sperm motility
More effective than other spermicides
1.8% lactic acid, 1% citric acid, 0.4% potassium bitartrate
Use within 1 hour prior to each act of intercourse
Limitations:
•
•

Cost: $270/box (#60), unlikely to be covered
Side Effects: vaginal burning/itching/vaginitis, UTI

Point-of-care Resources:

US Medical Eligibility Criteria (MEC) and Selected
Practice Recommendations (SPR):
Evidence based guidance for contraceptive use, last
updated in 2016 based on WHO guidelines
•
•

•
•

To base family planning practices on the best available evidence
To address misconceptions regarding who can safely use
contraception
To remove unnecessary medical barriers
To improve access and quality of care in family planning

U.S. MEC: Categories
1

No restriction for the use of the contraceptive
method for a woman with that condition

2

Advantages of using the method generally
outweigh the theoretical or proven risks

3

Theoretical or proven risks of the method
usually outweigh the advantages – not usually
recommended unless more appropriate
methods are not available or acceptable

4

Unacceptable health risk if the contraceptive
method is used by a woman with that
condition

2016 U.S. MEC and SPR App

Example: Smoking and Contraceptive Use

Cu IUD: Copper IUD;
LNG-IUD: Levonorgestrel IUD;
DMPA: Depo-Medroxyprogesterone Acetate;
POPs: Progestin-only pills;
CHCs: Combined hormonal contraceptives including pills, patch, and ring

Point-of-care Resources:

Reproductive Health Access Project (RHAP):

Overcoming clinician-level barriers:
Identify opportunities for additional training
• Standardize assessment of pregnancy intendedness in
patients with reproductive potential
•

•

avoid subjectively risk stratifying

Use a patient-centered approach to reproductive planning
• Schedule a separate visit if time is an issue
• Access real-time resources to help navigate options and
safety
•

Summary:
• Most women can safely use most contraceptive methods
• Discuss all methods - always honor a patient’s choice
• Be proactive with assessing pregnancy intentions and
contraception needs

• There are several new options available, but need to understand
the benefits and risks associated with each

• Access to easily available, evidence-based contraceptive data
can help clinicians decrease barriers to choosing patientcentered, effective contraceptive methods
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